You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

May 27, 2021

Indonesia Updates Its Drug Advertising Guidelines

Subscribe to Updates

In February 2021, Indonesia’s National Agency for Drug and Food Control (Badan Pengawas Obat dan Makanan, or BPOM) issued updated guidelines for the advertising of pharmaceutical products. Regulation 2/2021 concerning the Supervision of Drug Advertising Guidelines, which came into effect on February 3, 2021, improves the process for the submission and consideration of advertisement approval requests, expands the categories of media and drugs that are not allowed to be advertised, defines supervisions and sanctions, and better clarifies drug labeling and advertisement to prevent pharmaceutical companies from mislabeling drugs and clamp down on drug advertisement violations online.

At the same time, BPOM revoked Regulation 8/2017 concerning the Supervision of Drug Advertising Guidelines. This old version from 2017 was updated by the new regulation in several important ways.

Online Application System for Advertisement Approval

BPOM now operates an online advertisement approval application system known as SIAPIK (from its full name, Sistem Aplikasi Persetujuan Iklan). The use of this online system, which is available at https://siapik.pom.go.id, is a step forward from the previous practice in which advertisement applications had to be filed in person.

BPOM Regulation 2/2021 regulates the submission of advertisement approval applications via the SIAPIK website. These applications must include a marketing authorization approval letter, the approved label or label design, and the advertising design. Advertising documents in English are accepted, but documentation in any other foreign (or local) language must be translated into Bahasa Indonesia. Applications should also include supporting documents containing certain information that is not related to the use of drugs, if required by the officer for verification.

After the documents are submitted, BPOM evaluates the advertisement approval using the appropriate process for the category into which the advertisement falls. Those in the “minor” category include advertisements with new concepts that do not have the potential to cause misinterpretation, as well as variations (such as small alterations to the information, and other insignificant changes) on advertisements that have already been approved. Those in the “major” category include advertisements with new concepts that have the potential to lead to wrong interpretations, and variations of advertisements (or meaningful changes) that have already been approved and have undergone no other notable change (e.g., in advertisement media, in reduction of claims, or through shortening of duration that could alter interpretations of the advertisement).

The evaluation period is 10 working days for minor category advertisements and 25 working days for major category advertisements—both significantly shorter than the 60 days for evaluation (regardless of category) specified in the previous regulation.

Evaluation results are then issued electronically—approved if the application has met all the requirements, or rejected if the application has failed to do so. An approval of an advertisement is valid for as long as the marketing authorization of the drug lasts and as long as the advertisement still meets the criteria and requirements.

The SIAPIK system also provides a “notification service,” which applicants can use to apply for renewal of unchanged advertisements or approval for variations to already-approved advertisements, if the changes are to:

  • design or layout, without changing the claims or information contained in the advertisement;
  • the cast appearing in the advertisement;
  • publication means, without any change in advertisement media as defined in article 7(2), 7(3), and 7(4) (see discussion of media categories below); or
  • reduction of claims or shortening of duration that does not result in a change to the interpretation or meaning of the advertisement.

Applications using the notification service are processed automatically via the SIAPIK system, with independent evaluation by the applicant (that is, self-assessment without BPOM evaluation) within one working day.

Media Category for Drug Advertisements

BPOM Regulation 2/2021 also expands the definitions of advertising publication media in which drugs can be advertised to three broad categories:

  1. visual media
  2. audio media (which includes audio accompanied by a static image online), and
  3. audiovisual media (such as an online video).

This is a significant change from the previous regulation’s media categories of only printed, electronic, and outdoor media.

Advertisements in the form of interactive communication (e.g., telephone, social media, chat rooms, and instant messaging), whereby information is transmitted between the advertiser and the public, are permitted as long as they meet all regulatory requirements, contain complete and truthful information,  and are in compliance with the approved advertisement.

Unlike BPOM Regulation 8/2017, the new regulation requires advertisements using visual media to provide a contact for customer service.

Advertising Controls and Prohibitions for Specific Drugs

The list of specific drugs that require additional information in their advertisements remains the same, but in the new regulation this has been moved into the body (instead of an appendix). These drugs include the following:

  • Cough medicine or flu medicine
  • Asthma medication
  • Indigestion medicine
  • Anthelmintic
  • Topical drugs for fungal infections
  • Eye drops
  • Mouthwash
  • Sore throat medication
  • Bruise medicine
  • Anemia medicine
  • Laxatives
  • Motion sickness medication
  • Malaria drugs
  • Diarrhea medicine

Advertisements for prescription drugs, narcotics, and psychotropic drugs are exempted from having to include specific information if the advertisements are addressed to healthcare workers.

One change reflected in the new regulation is an expansion of the types of drugs prohibited from being advertised to the public. In Regulation 8/2017, “G-list drugs,” or prescription drugs, are prohibited from being advertised to the public. In Regulation 2/2021, this prohibition on public advertisements covers prescription drugs, narcotics, and psychotropic drugs.

Supervision of Advertisements

Officers continue to have the authority to monitor airing advertisements and re-evaluate approved advertisements. However, Regulation 2/2021 allows the public to participate in advertisement supervision as well by providing information or reports on suspected advertisement violations. The report should be submitted to the head of BPOM electronically to the official BPOM email address for public complaints ([email protected]) or by telephone (1500533). The information can also be submitted in writing to the director of safety, quality and import export control of drugs, narcotics, psychotropics, precursors, and addictive substances.

Sanctions

BPOM Regulation 2/2021 stipulates a number of administrative sanctions, depending on the severity of a violation. At the lower end of the scale are warnings (from a written notice to a more serious warning), followed by orders to correct, stop, or withdraw published advertisements. Offenders may also be punished by a temporary suspension of advertising activities, or a freezing or revocation of a marketing authorization permit.

Conclusion

While Regulation 2/2021 does not represent a fundamental change to drug advertising in Indonesia, there are several significant updates that pharmaceutical companies need to be aware of before planning an advertising campaign in Indonesia or submitting a drug advertisement application. The regulations for using the SIAPIK online system, amended categories and prohibitions, and public involvement in supervising advertisements are important updates that both have the potential to affect companies’ advertising plans and help maintain the relevance and effectiveness of Indonesia’s drug advertising regulatory environment.

Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

August 23, 2022
On July 13, 2022, the Vietnamese government issued Decree No. 46/2022/ND-CP amending and supplementing some articles of Decree No. 13/2020/ND-CP providing detailed guidance on the Law on Animal Husbandry (“Decree 46”). The new decree took effect on the issuance date. Among the changes introduced by Decree 46 are a number related to animal feed. Recognition of Testing Methods of Exporting Countries Decree 46 clarifies the steps to recognize animal feed testing methods of laboratories in exporting countries. Under the amended regulations, the Department of Livestock Production (DLP) will organize an assessment team to appraise each dossier for recognition of animal feed testing methods within 30 days of receipt of a complete dossier. If the dossier lacks required information or authenticity, the DLP will organize a practical assessment team at the exporting country’s testing laboratory. If the dossier passes the assessment, within five working days from the completion of the assessment, the DLP will issue a decision on recognition of the testing method. The validity of this decision has been lengthened from three years to five years. State Inspection of Animal Feed Quality Process of State Inspection Decree 46 specifies the process to conduct state inspection of the quality of imported animal feed by unifying the regulations stipulated in the related legal documents listed in Decree 13. The process includes the submission of a state inspection dossier, timelines to receive feedback from the inspection authority, and further steps that can be taken upon receiving acceptance or refusal decisions from the authority. For traditional animal feed and complete compound animal feed, imported shipments are customs-cleared as soon as the importer completes the customs procedures. Within 15 days from the customs clearance date, the importer must submit the conformity assessment results. The importer has complete responsibility for the conformity assessment results, and
Read More
August 18, 2022
Practical Law has published an updated online version of Agricultural Law in Thailand, a Q&A-style guide that provides detailed overviews of Thailand’s agriculture laws and regulations. The Thailand overview is one of approximately twenty such guides to jurisdictions worldwide, covering key practical issues related to the legal environment for agricultural operations. The Thailand section, which was written by lawyers at Tilleke & Gibbins, covers the following topics: Agricultural policy Acquisition of agricultural companies Acquisition of agricultural land Crop seed business Plant variety rights Genetically modified crops Animal and animal welfare issues Agricultural safety and product liability Practical Law, produced by Thomson Reuters, is a comprehensive global legal resource for business lawyers. The platform features a wide range of guides covering hundreds of jurisdictions and practice areas. The full Agricultural Law in Thailand chapter can be accessed on the Practical Law website.
Read More
August 9, 2022
In late 2021, the government of Vietnam issued Decree 98 on the management of medical devices (Decree No. 98/2021/ND-CP dated November 8, 2021), which came into force on January 1, 2022. This is the primary legislation on medical devices in Vietnam. To provide necessary guidance and elaboration on the implementation of Decree 98, the Ministry of Health recently issued Circular No. 05/2022/TT/BYT dated August 1, 2022 (“Circular 05”), which took effect on the same day. The most notable aspect of Circular 05 is that it unifies, in a single legislative document, previous regulations on medical devices that were scattered in multiple circulars issued by the Ministry of Health (Circular No. 39/2016/TT-BYT dated October 28, 2106; Circular No. 46/2017/TT-BYT dated December 15, 2017, as amended by Circular No. 23/2021/TT-BYT dated December 9, 2021; and Circular No. 33/2020/TT-BYT dated December 31, 2020). The effectiveness of these circulars was terminated when Circular 05 took effect. Circular 05 sets out regulations and principles for the classification of medical devices, and adds or supplements the following lists: List of in vitro diagnostic medical devices (IVD) not subject to quality assessment by Vietnamese competent authorities when registering under the quick registration procedure. List of class B, C and D medical devices allowed to be traded as normal goods. List of medical devices required to be accredited for safety and technical functions before use. List of medical devices requiring import permit licenses. While Circular 05 does not introduce major changes to the previous regulations, the consolidation and up-to-date guidance on Decree 98 will simplify the task of registration and circulation for medical device companies doing business in Vietnam.
Read More
August 4, 2022
Cosmetics have become an essential feature of the modern lifestyle led by many consumers in Cambodia. Every day, a wide range of new cosmetic brands, variants, and formats enter the Cambodian market, catering to a growing consumer base. The market generally relies on the import of foreign cosmetic brands, making Cambodia an attractive market for overseas cosmetics companies, but local brands are on the rise as well. Alongside the significant growth of the cosmetics market in Cambodia, and the Royal Government’s continuing push to increase consumer protection in Cambodia, in 2022, the Ministry of Commerce (MOC) issued Prakas No. 0064 on the Requirements for Cosmetic Distribution (the Prakas). The Prakas applies to both locally manufactured and imported cosmetics, and both individual and businesses that trade in cosmetics. The Prakas aims to regulate cosmetics and cosmetic business activities, to ensure that cosmetics distributed in Cambodia are of good quality and safe for use.  The key points contained in the Prakas are summarized below. Legal Obligations for Trading Cosmetics Any person trading in cosmetics, including wholesale or retail, and those that offer cosmetics as gifts or for testing, must ensure that the products are safe and meet the legal labelling requirements. Anyone trading cosmetics must respect the Law on Consumer Protection, with the Prakas highlighting key aspects of that law and referring to the applicable penalties under that law. Online sellers of cosmetics must obtain an additional approval letter (for individuals) or a license (for legal entities) to operate an online business, issued by the MOC. In addition, they require a certificate for providing online services from the Ministry of Post and Telecommunications. Interestingly, the Prakas does not refer to the cosmetic business licensing required under regulations issued by the Ministry of Health. As the Prakas does not outright contradict these
Read More